Quabodepistat is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Pulmonary Tuberculosis.

TBA-7371 is under development for the treatment of pulmonary tuberculosis caused by mycobacterium tuberculosis. The drug candidate is 1,4 azaindoles. It is administered through oral route in the form ...

Introduction In the realm of sports nutrition and energy supplementation, D-Ribose Powder has emerged as a popular choice for ...

In the energy sector, where innovation and environmental responsibility are constantly evolving, energy public relations (PR) plays a pivotal role in shaping how companies are perceived by both the ...

Deriaz, R. E., Overend, W. G., Stacey, M., Teece, E. G., and Wiggins, L. F., J. Chem. Soc., 1879 (1949). Prins, D. A., Helv. Chim. Acta, 29, 1 (1946).

Cutting-edge tuberculosis therapy: Researchers test quabodepistat combinations, aiming for shorter, safer treatments to combat drug resistance and improve patient outcomes. Study: Safety ...

If you’re looking for a supplement to support your neurotransmitters and energy levels, NOW Supplements NADH 10 mg with 200 mg D-Ribose is a great option. We have been using NOW Supplements NADH ...